SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SonoSight (SONO), Handheld ultrasound for the masses
SONO 18.05-2.2%Dec 22 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sam who wrote (334)2/2/2000 9:45:00 AM
From: TRIIBoy  Read Replies (1) of 365
 
Q4 conference call review:

Overall solid conference call.

1)Some key points are that it beat my own sales estimate of $9 million and it was revealed in the call that they have experienced some problems with PSS, their distributor. These issues are now resolved, but the fact that they did $9.4 million and had problems mean they really had a great quarter.

2)Accounts Recievables less than quarterly sales meaning they did not cook the books in way shape or form, inventories was also very low. In fact, management stated that there was very little finished goods inventory left.

3)They carried over a "substantial" backlog into the first quarter

4)Sell-through was excellent with very little inventory left with distributors

5)hired a direct sales force of 27 people to sell directly to hospitals, they will officially hit the pavement on February 21.

6)They discovered a new "high-frequency" upgrade for their product that will enable them to use SONO 180 for surgery. Vascular, cardiothoracic and general surgery. this is a completely new application for SONO.

7)Comfortable with revenue forecasts for 2000.

Much more information on the call listen for yourself:

Playback number: 1-800-475-6701, access code: 494428.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext